Chemotherapy Induced Anemia - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 55

Chemotherapy Induced Anemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia. Chemotherapy Induced Anemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Anemia.
- A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Induced Anemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Chemotherapy Induced Anemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Chemotherapy Induced Anemia 8
Chemotherapy Induced Anemia Therapeutics under Development by Companies 10
Chemotherapy Induced Anemia Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Chemotherapy Induced Anemia Therapeutics – Products under Development by Companies 17
Chemotherapy Induced Anemia Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Chemotherapy Induced Anemia Therapeutics Development 19
Kyowa Hakko Kirin Co., Ltd. 19
Reliance Life Sciences Pvt. Ltd. 20
3SBio Inc. 21
ProMetic Life Sciences Inc. 22
Lipoxen PLC 23
Acceleron Pharma, Inc. 24
Therapure Biopharma Inc. 25
Chemotherapy Induced Anemia – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
sotatercept - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Erythropoietin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PBI-1402 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ErepoXen - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Epoetin alfa + Cisplatin + Brachytherapy + Radiation therapy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
darbepoetin alfa - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TXA127 + Erythropoietin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
erythropoietin biosimilar - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TBI-304 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
darbepoetin alfa - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Chemotherapy Induced Anemia Therapeutics – Drug Profile Updates 43
Chemotherapy Induced Anemia Therapeutics – Discontinued Products 45
Chemotherapy Induced Anemia Therapeutics - Dormant Products 46
Chemotherapy Induced Anemia – Product Development Milestones 47
Featured News & Press Releases 47
Jan 31, 2012: Kyowa Hakko Kirin Withdraws Domestic Application For Additional Chemotherapy-Induced Anemia Indication For NESP 47
Jul 11, 2011: 3SBio Receives SFDA Approval For High-Dose EPIAO 47
Jun 02, 2011: Acceleron And Celgene Initiate Phase II/III Study Of ACE-011 To Treat Chemotherapy-Induced Anemia In Patients With Lung Cancer 48
Jun 06, 2010: Alder's ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia In Phase IIa Clinical Trial In NSCLC Patients 48
Mar 02, 2010: Lipoxen Initiates Phase II Trial Of ErepoXen In India 49
Feb 22, 2010: Retacrit Received a Positive Opinion From the European Committee for Medicinal Products for Human Use (CHMP) for Subcutaneous (SC) use in Renal Anaemia 50
Dec 01, 2009: Acceleron Pharma To Present Clinical Trial Results Of ACE-011 At The 51st Annual Meeting Of The American Society Of Hematology 50
Jul 28, 2009: Acceleron and Celgene Initiate Phase II Study of ACE-011 to Treat Chemotherapy-Induced Anemia 50
May 06, 2009: Lipoxen Plc Announces Positive Phase I Clinical Trial Results For ErepoXen 51
Jun 16, 2008: Lipoxen Receives Approval To Conduct Second Phase I Trial Of Its Long-Acting Erythropoietin (EPO), ErepoXen, In Canada 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables
Number of Products Under Development for Chemotherapy Induced Anemia, H2 2012 8
Products under Development for Chemotherapy Induced Anemia – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Kyowa Hakko Kirin Co., Ltd., H2 2012 19
Reliance Life Sciences Pvt. Ltd., H2 2012 20
3SBio Inc., H2 2012 21
ProMetic Life Sciences Inc., H2 2012 22
Lipoxen PLC, H2 2012 23
Acceleron Pharma, Inc., H2 2012 24
Therapure Biopharma Inc., H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Chemotherapy Induced Anemia Therapeutics – Drug Profile Updates 43
Chemotherapy Induced Anemia Therapeutics – Discontinued Products 45
Chemotherapy Induced Anemia Therapeutics – Dormant Products 46

List of Figures
Number of Products under Development for Chemotherapy Induced Anemia, H2 2012 8
Products under Development for Chemotherapy Induced Anemia – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Customers who bought this item also bought

• Chemotherapy Induced Anemia - Pipeline Review, H1 2012
• Anemia - Pipeline Review, H2 2012
• Chemotherapy Induced Anemia - Pipeline Review, H2 2011
• Renal Anemia - Pipeline Review, H2 2012
• Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2012
• Iron Deficiency Anemia - Pipeline Review, H2 2012
• Fanconi Anemia - Pipeline Review, H2 2012
• Aplastic Anemia - Pipeline Review, H2 2012
• Iron Deficiency Anemia - Pipeline Review, H1 2013
• Acute Pain - Pipeline Review, H2 2012